Start Date
October 31, 2009
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
OXALIPLATIN (SR96669)
Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
5-FLUOROURACIL (5-FU)
Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
LEUCOVORIN (LV)
Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
BEVACIZUMAB
Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
Sanofi-Aventis Administrative Office, Laval
Lead Sponsor
Sanofi
INDUSTRY